Celsion Corporation (CLSN)

[Biobonic]

When deciding on treatment, health care providers consider the cause and severity of the neutropenia. Mild cases may not need any treatment.

Other cases can be life threatening.

No estimates of efficacy, but the longer a trial progresses the better the difference between the two groups.

Q2 2019 Results - Earnings Call Transcript
While it is possible for OPTIMA study to be declared successful at the first interim, the probability of success improves with the number of patients evaluated. While we remain optimistic for a positive trial reserved in October the likelihood of success is much greater at the second interim analysis, which is expected to occur in the first half of 2020 assuming the current rate of death that we're seeing in the trial population.

Just coming up to speed on Celsion.